Sanofi Consumer Healthcare India Ltd
Sanofi Consumer Healthcare India Ltd operates in the pharmaceuticals industry, focusing on the development, manufacturing, and distribution of over-the-counter (OTC) and prescription drugs, primarily in the Indian market.
Business. Sanofi Consumer Healthcare India Ltd (SNOF.NS) is a pharmaceutical company operating within the Healthcare sector, specifically engaged in the pharmaceuticals industry. The firm generates revenue through the sale of products and is headquartered in India. It is primarily listed on the National Stock Exchange of India (NSE). Specific details regarding operating segments or geographic revenue breakdowns are not available.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Sanofi Consumer Healthcare India Ltd (SNOF.NS) is a pharmaceutical company operating within the Healthcare sector, specifically engaged in the pharmaceuticals industry. The firm generates revenue through the sale of products and is headquartered in India. It is primarily listed on the National Stock Exchange of India (NSE). Specific details regarding operating segments or geographic revenue breakdowns are not available.
Sanofi Consumer Healthcare India Ltd maintains a strong liquidity position, with a current ratio of 3.85 and cash and equivalents amounting to INR 3.75 billion, which significantly exceeds its total liabilities of INR 1.63 billion. The company's liquidity is further supported by a free cash flow of INR 1.18 billion, indicating robust cash generation from operations.
In terms of profitability, the company demonstrates a return on equity (ROE) of 62.53% and a return on assets (ROA) of 43.89%, both of which are well above the typical thresholds for the pharmaceutical industry. These figures suggest that the company is effectively utilizing its equity and asset base to generate returns.
The company's revenue is primarily concentrated in the Indian market, with no disclosed international operations. This geographic concentration may expose the company to local regulatory and economic risks, although it also allows for focused market penetration and brand strength.
Looking ahead, the company is expected to maintain a stable growth trajectory, supported by its strong cash flow and low debt levels. While no specific revenue growth percentages are provided, the company's operating cash flow of INR 1.75 billion and capital expenditure of INR 76 million suggest a conservative approach to reinvestment and expansion.
The company's risk profile is characterized by low liquidity and dilution risks. There are no immediate filing-based liquidity or dilution flags, and the debt-to-equity ratio of 0.06 indicates a conservative capital structure with minimal leverage.
Recent events and filings do not indicate any significant changes in the company's operations or financial strategy. The company's strong buy recommendation from analysts, with a mean price target of INR 5,855, suggests positive sentiment among market participants.
- Sanofi Consumer Healthcare India Ltd has a strong liquidity position with a current ratio of 3.85 and INR 3.75 billion in cash and equivalents.
- The company's profitability is robust, with a return on equity of 62.53% and a return on assets of 43.89%.
- Revenue is concentrated in the Indian market, which may pose regulatory and economic risks.
- The company is expected to maintain a stable growth trajectory with conservative capital expenditures.
- The company has low liquidity and dilution risks, with a debt-to-equity ratio of 0.06.
- Analysts have a strong buy recommendation for the company, with a mean price target of INR 5,855.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 120,80 |
| Revenue | —no estimate | —no estimate | 9,9B INR |
| Operating income | —no estimate | —no estimate | 3,7B INR |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Sanofi Consumer Healthcare India Ltd Market data — financials · 2026-05-29
- Sanofi Consumer Healthcare India Ltd Market data — analyst estimates · 2026-05-29